In the most recent trading session, Novavax (NVAX) closed at $6.41, indicating no shift from the previous trading day.

The FDA is expected to unpause the only protein-based COVID-19 vaccine's transition from emergency approval to full approval.

Shares of Novavax Inc. NVAX slipped 3.90% to $6.41 Thursday, on what proved to be an all-around great trading session for the ...

Novavax Inc. closed 72.05% short of its 52-week high of $23.86, which the company reached on June 6th.

The President Donald Trump administration's request for Novavax Inc. to conduct new clinical trials for its COVID-19 vaccine ...

Novavax’s (NVAX) stock is up after the FDA requested additional data for its COVID-19 vaccine. Unusual at first glance, the phrase “additional data” tends to inspire fear among biotechnology investors ...

Kennedy won Senate confirmation to his job, in part, by promising not to change the nation’s vaccine schedule. Since taking ...

Novavax shows financial improvement but faces vaccine challenges. Read why I rated NVAX stock as 'Hold' and what risks and ...

Novavax, Inc. (NVAX) shares jumped nearly 12.6% over the past week, leading to a surge in retail investor chatter following ...

Novavax faces a setback as the FDA requests an additional trial for COVID-19 vaccine approval. Read more here.

Federal regulators have asked Novavax to complete an additional clinical trial on its COVID-19 vaccine after previously ...

The cost of a new randomized trial to evaluate the vaccine’s ability to prevent disease could run into tens of millions of ...